Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.lilly.com.

Nov 8, 2023 · Eli Lilly says tirzepatide, a drug used to treat type 2 diabetes, also leads to substantial weight loss in diabetes patients. The drug, called Mounjaro for diabetes, will be called Zepbound for...

Jan 8, 2025 · Zepbound and Mounjaro both contain tirzepatide and are both made by Eli Lilly and Company. The key difference lies in their FDA-approved uses and branding strategy. The key considerations when choosing between Mounjaro and Zepbound are: Prior authorization requirements. Primary indication: Treatment of type 2 diabetes in adults.

While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint. Mounjaro represents the first new class of diabetes medicines introduced in nearly a decade and is expected to …

Mounjaro is a prescription medicine available as a pre-filled single-dose pen in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL injection. For more information, call 1-833-807-MJRO (833-807-6576) or go to www.mounjaro.lilly.com.

Nov 8, 2023 · A new version of the popular diabetes treatment Mounjaro from Eli Lilly can be sold as a weight-loss drug, U.S. regulators announced Wednesday.

Nov 8, 2023 · A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly’s drug, named Zepbound.

Jan 4, 2024 · On Thursday, the drugmaker introduced the new platform, LillyDirect, which will offer at-home prescription delivery service to create more access to Eli Lilly’s Mounjaro and Zepbound — brand...

Jul 27, 2023 · Eli Lilly has already proven that its diabetes drug Mounjaro can help overweight and obese people lose weight, findings that could lead to a U.S. approval later this year.

U.S. drug regulators have approved expanding the use of Eli Lilly’sLLY-0.08 % decrease; red down pointing triangle diabetes drug Mounjaro to include the treatment of obesity.